Design, synthesis and evaluation of caffeic acid phenethyl ester-based inhibitors targeting a selectivity pocket in the active site of human aldo–keto reductase 1B10
Inhibitors of a human aldo–keto reductase, AKR1B10, are regarded as promising therapeutics for the treatment of cancer, but those with both high potency and selectivity compared to the structurally similar aldosereductase (AKR1B1) have not been reported. In this study, we have found that, among honeybee propolis products, caffeic acid phenethyl ester (CAPE) inhibited AKR1B10 (IC50 = 80 nM) with 7-fold
人醛基酮还原酶抑制剂AKR1B10被认为是治疗癌症的有前途的疗法,但与结构相似的醛糖还原酶(AKR1B1)相比,具有高效能和选择性的抑制剂尚未见报道。在这项研究中,我们发现,在蜂胶产品中,咖啡酸苯乙酯(CAPE)抑制AKR1B10(IC 50 = 80 nM)的选择性是AKR1B1的7倍。基于AKR1B10中停靠的CAPE模型,设计,合成了其衍生物并评估了其抑制效力。其中,3-(4-羟基-2-甲氧基苯基)丙烯酸3-(3-羟基苯基)丙酯(10c)是最有效的竞争抑制剂(K i = 2.6 nM),对AKR1B10的选择性是AKR1B1的790倍。的分子对接10C和AKR1B10残基的位点定向诱变建议,2-甲氧基和3-羟基基团之间的相互作用10C和酶的Val301和Gln114,分别是用于所述抑制剂的选择性很重要。此外,亚μM浓度10c显着抑制了过表达AKR1B10的细胞的法呢素代谢和细胞增殖。